Celldex Therapeutics to Present Clinical Results at 2017 ASCO Annual Meeting
May 17 2017 - 5:01PM
Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that
clinical results from the single-agent cohort of the Phase 2 study
of glembatumumab vedotin in patients with metastatic melanoma and
the Phase 1 dose-escalation study of varlilumab and nivolumab in
multiple solid tumors, will be presented in oral presentations at
the 2017 American Society of Clinical Oncology (ASCO) Annual
Meeting being held June 2-6, 2017 in Chicago. Information in the
abstracts is current as of the time of submission in February 2017.
- Abstract #109: “A Phase 2 study of glembatumumab vedotin, an
antibody-drug conjugate (ADC) targeting gpNMB, in advanced
melanoma.” Patrick A. Ott, M.D., Ph.D., Clinical Director of
Dana-Farber Cancer Institute’s Melanoma Center and its Center for
Immuno-Oncology, and Assistant Professor of Medicine at Harvard
Medical School, will present results during the Clinical Science
Symposium “Hitting the Target: Antibody-Drug Conjugates,” which
begins on Monday, June 5, 2017 at 9:45 a.m. CDT.
- Abstract #3007: “Clinical results with combination of anti-CD27
agonist antibody, varlilumab, with anti-PD1 antibody nivolumab in
advanced cancer patients.” Rachel E. Sanborn, M.D., co-director of
the Providence Thoracic Oncology Program at Providence Cancer
Center in Portland, Ore., will present results during the session
“Developmental Therapeutics—Immunotherapy,” which begins on Monday,
June 5, 2017 at 1:15 p.m. CDT.
About Celldex Therapeutics, Inc.
Celldex is developing targeted therapeutics to address
devastating diseases for which available treatments are inadequate.
Our pipeline includes antibodies, antibody-drug conjugates and
other protein-based therapeutics derived from a broad set of
complementary technologies which have the ability to engage the
human immune system and/or directly inhibit tumors to treat
specific types of cancer or other diseases. Visit
www.celldex.com.
Company Contact
Sarah Cavanaugh
Vice President of Investor Relations & Corp Communications
Celldex Therapeutics, Inc.
(781) 433-3161
scavanaugh@celldex.com
Charles Liles
Associate Director of Investor Relations & Corp Communications
Celldex Therapeutics, Inc.
(781) 433-3107
cliles@celldex.com
Media Contact
Dan Budwick
Founder, 1AB Media
(973) 271-6085
dan@1abmedia.com
Celldex Therapeutics (NASDAQ:CLDX)
Historical Stock Chart
From Apr 2024 to May 2024
Celldex Therapeutics (NASDAQ:CLDX)
Historical Stock Chart
From May 2023 to May 2024